Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab. 

New drug allows patients to self-treat PSVT. About 2 million people in the U.S. have been diagnosed with condition.

Promoting preventive care among young adult men during critical periods of their life may be the key to reducing rates of cardiovascular disease. 

STS late-breaking study found BITA and SITA+RA have similar long-term survival, but age plays a role in which to choose.

The Amend device from Valcare Medical has a closed ring shape similar to the annuloplasty rings used to treat MR during open-heart surgeries. These early patients will be followed for a total of five years.

Researchers explored data from more than 1,000 patients with calcified coronary artery disease who required plaque modification. IVL and atherectomy were linked to comparable success rates, but adverse events were less likely with IVL.

Cardiac complications after noncardiac surgeries are a significant concern, especially as patients keep living longer and surgical volumes continue to rise.

Early research suggests a single injection could reduce both brain damage and inflammation if delivered after a patient experiences a stroke. Much more research is still needed, but the new therapy showed significant potential. 

The new certification is focused on the importance of high-quality care and real-world patient outcomes. It will be based on the same data care teams already submit if they participate in the STS Adult Cardiac Surgery Database, ACC CathPCI Registry or STS/ACC TVT Registry.

“This is not about alarming people,” one researcher said. “It’s about recognizing an environmental factor that may be contributing to high blood pressure in some communities and making sure it’s part of the public health conversation."